Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Delta-8-THCM

From Wikipedia, the free encyclopedia

Delta-8-THCM
Identifiers
  • (6aR,10aR)-1-methoxy-6,6,9-trimethyl-3-pentyl-6a,7,10,10a-tetrahydrobenzo[c]chromene
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC22H32O2
Molar mass328.496 g·mol−1
3D model (JSmol)
  • CCCCCC1=CC2=C([C@@H]3CC(=CC[C@H]3C(O2)(C)C)C)C(=C1)OC
  • InChI=1S/C22H32O2/c1-6-7-8-9-16-13-19(23-5)21-17-12-15(2)10-11-18(17)22(3,4)24-20(21)14-16/h10,13-14,17-18H,6-9,11-12H2,1-5H3/t17-,18-/m1/s1
  • Key:GRLARWXSTOXAGR-QZTJIDSGSA-N

Delta-8-THCM (O-Methyl-Δ8-THC) is a chemical compound related to phytocannabinoids found in Cannabis. It has been sold as a designer drug, first identified in Sweden in June 2024.[1] However, it is a known compound which has been well established to almost entirely lack cannabinoid-like effects in mice, rats and monkeys,[2][3] unlike the dimethylheptyl analogue L-759,633 which is a selective agonist for CB2 and has antiinflammatory but not psychoactive effects.[4]

See also

[edit]

References

[edit]
  1. "European Drug Report 2025 – Full Book" (PDF). European Union Drugs Agency (euda.europa.eu). 6 June 2025.
  2. Mechoulam R, Edery H (1973). "Structure-Activity Relationships in the Cannabinoid series.". In Mecoulam R (ed.). Marijuana Chemistry, Pharmacology, Metabolism, and Clinical Effects. New York: Academic Press. pp. 101–136.
  3. Compton DR, Prescott WR, Martin BR, Siegel C, Gordon PM, Razdan RK (November 1991). "Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol". Journal of Medicinal Chemistry. 34 (11): 3310–3316. doi:10.1021/jm00115a023. PMID 1659638.
  4. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, et al. (February 1999). "Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630". British Journal of Pharmacology. 126 (3): 665–672. doi:10.1038/sj.bjp.0702351. PMC 1565857. PMID 10188977.